Your browser is no longer supported. Please, upgrade your browser.
Settings
SMMT [NASD]
Summit Therapeutics Inc.
Index- P/E- EPS (ttm)-0.77 Insider Own69.60% Shs Outstand82.58M Perf Week-14.75%
Market Cap691.41M Forward P/E- EPS next Y-0.01 Insider Trans19.99% Shs Float25.21M Perf Month24.68%
Income-63.90M PEG- EPS next Q-0.00 Inst Own9.60% Short Float1.97% Perf Quarter5.41%
Sales0.70M P/S987.73 EPS this Y-80.90% Inst Trans1.81% Short Ratio2.37 Perf Half Y39.18%
Book/sh0.96 P/B7.10 EPS next Y- ROA- Target Price4.50 Perf Year98.26%
Cash/sh0.65 P/C10.41 EPS next 5Y- ROE- 52W Range2.91 - 12.30 Perf YTD45.11%
Dividend- P/FCF- EPS past 5Y- ROI-66.60% 52W High-44.56% Beta0.63
Dividend %- Quick Ratio4.40 Sales past 5Y- Gross Margin- 52W Low134.33% ATR0.60
Employees79 Current Ratio4.40 Sales Q/Q-71.40% Oper. Margin- RSI (14)45.24 Volatility8.33% 9.65%
OptionableYes Debt/Eq0.00 EPS Q/Q53.80% Profit Margin- Rel Volume0.88 Prev Close7.11
ShortableYes LT Debt/Eq0.00 EarningsMar 17 BMO Payout- Avg Volume209.26K Price6.82
Recom2.00 SMA20-9.15% SMA505.08% SMA20027.31% Volume183,503 Change-4.08%
Jun-28-18Downgrade Janney Buy → Neutral
May-02-18Initiated Janney Buy
Apr-12-18Reiterated Needham Buy $30 → $27
Feb-13-18Initiated BTIG Research Buy $33
Jan-04-18Initiated SunTrust Buy $24
Dec-01-17Resumed H.C. Wainwright Buy $16
Nov-16-16Reiterated RBC Capital Mkts Outperform $26 → $29
Oct-05-16Reiterated Needham Buy $22 → $30
Sep-16-16Initiated H.C. Wainwright Buy $26
Mar-30-15Initiated Oppenheimer Outperform $28
Mar-30-15Initiated Needham Buy $22
Jun-08-21 11:07AM  
07:00AM  
Jun-03-21 08:00AM  
May-19-21 08:33AM  
May-18-21 07:00AM  
May-17-21 03:01PM  
08:00AM  
May-12-21 02:59PM  
May-06-21 08:00AM  
May-05-21 12:47PM  
Apr-21-21 08:04AM  
Mar-26-21 07:00AM  
Mar-17-21 07:00AM  
Dec-19-20 01:45PM  
Dec-16-20 08:32AM  
Nov-23-20 07:00AM  
Nov-16-20 04:05PM  
Nov-06-20 04:01PM  
Oct-30-20 09:16AM  
Oct-02-20 06:40PM  
Sep-29-20 07:00AM  
Sep-18-20 07:11AM  
Sep-17-20 07:00AM  
Aug-19-20 04:01PM  
Jul-16-20 07:00AM  
Jul-13-20 07:00AM  
Jun-08-20 07:00AM  
Jun-04-20 09:47PM  
Jun-02-20 05:45PM  
04:01PM  
Jun-01-20 11:30AM  
May-27-20 05:45PM  
May-19-20 05:45PM  
May-18-20 11:43AM  
May-13-20 12:52PM  
11:30AM  
May-06-20 05:45PM  
Apr-30-20 07:00AM  
Apr-27-20 11:30AM  
Apr-24-20 05:50PM  
Apr-17-20 08:37AM  
Apr-16-20 12:00PM  
Apr-14-20 09:15AM  
Apr-09-20 11:30AM  
Apr-08-20 11:01AM  
Apr-07-20 11:08AM  
09:25AM  
Mar-26-20 09:59AM  
Mar-25-20 11:08AM  
Mar-24-20 11:30AM  
Feb-26-20 07:00AM  
Feb-11-20 05:00AM  
Feb-10-20 09:15AM  
Feb-06-20 07:00AM  
Feb-04-20 07:00AM  
Jan-27-20 02:00AM  
Jan-24-20 07:00AM  
Jan-23-20 07:00AM  
Jan-20-20 09:15AM  
Jan-15-20 07:15AM  
Jan-07-20 07:00AM  
Dec-31-19 04:00AM  
Dec-30-19 02:00AM  
Dec-24-19 03:30AM  
02:01AM  
02:00AM  
Dec-23-19 07:00AM  
Dec-19-19 02:00AM  
Dec-17-19 07:00AM  
Dec-16-19 09:15AM  
Dec-06-19 07:24AM  
Nov-08-19 06:36AM  
Nov-06-19 07:00AM  
Nov-04-19 07:00AM  
Oct-22-19 11:02AM  
08:55AM  
Oct-16-19 07:00AM  
Oct-11-19 07:01AM  
07:00AM  
Oct-10-19 09:30AM  
Oct-08-19 07:30AM  
Oct-07-19 07:00AM  
Oct-03-19 07:00AM  
02:00AM  
Oct-01-19 10:07AM  
Sep-25-19 07:00AM  
Sep-24-19 07:00AM  
Sep-18-19 02:00AM  
Sep-04-19 07:00AM  
Aug-07-19 09:39AM  
Aug-01-19 07:00AM  
Jul-17-19 07:00AM  
Jul-09-19 07:00AM  
Jul-01-19 09:13AM  
Jun-20-19 11:13AM  
07:00AM  
Jun-19-19 07:00AM  
Jun-18-19 07:00AM  
Jun-12-19 07:00AM  
Jun-07-19 09:27AM  
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DUGGAN ROBERT WChief Executive OfficerMay 12Buy5.2411,365,92159,557,42667,662,454May 14 04:39 PM
Zanganeh MakyChief Operating OfficerMay 12Buy5.24389,0772,038,7632,643,319May 14 04:37 PM
Powell David JonathanChief Scientific OfficerNov 30Option Exercise1.7913,71324,54613,713Dec 01 07:45 PM
Powell David JonathanChief Scientific OfficerNov 30Sale4.4413,71360,8860Dec 01 07:45 PM
Powell David JonathanChief Scientific OfficerNov 27Option Exercise1.8629,56955,08929,569Dec 01 07:45 PM
Powell David JonathanChief Scientific OfficerNov 27Sale4.3929,569129,8080Dec 01 07:45 PM
Powell David JonathanChief Scientific OfficerNov 25Option Exercise1.9212,07023,17412,070Nov 25 07:51 PM
Powell David JonathanChief Scientific OfficerNov 25Sale4.3212,07052,1420Nov 25 07:51 PM
Powell David JonathanChief Scientific OfficerNov 24Option Exercise1.9211,37421,83811,374Nov 25 07:51 PM
Powell David JonathanChief Scientific OfficerNov 24Sale4.2111,37447,8850Nov 25 07:51 PM
Powell David JonathanChief Scientific OfficerNov 23Option Exercise1.926,98713,4156,987Nov 25 07:51 PM
Powell David JonathanChief Scientific OfficerNov 23Sale4.406,98730,7430Nov 25 07:51 PM
DUGGAN ROBERT WChief Executive OfficerNov 06Buy3.3414,071,85646,999,99956,296,533Nov 10 04:25 PM